Candid Pharmaceuticals

Candid Therapeutics is a clinical-stage biotechnology company dedicated to developing T-cell engagers (TCEs) for the treatment of autoimmune diseases. Launched in 2024 with a significant $370 million capital raise, the company focuses on depleting B-cells more effectively than traditional monoclonal antibodies by redirecting T-cells to eliminate pathogenic B-cell populations. Its lead programs, CND-101 and CND-201, are bispecific antibodies targeting CD20 and BCMA, respectively, which have already demonstrated clinical proof-of-mechanism in early trials. Candid aims to revolutionize the standard of care for conditions such as systemic lupus erythematosus and rheumatoid arthritis by leveraging insights from oncology to treat immunology. The company was founded by industry veterans with a track record of successful drug development and exits in the biopharmaceutical sector.